Obermatt

Zoetis

NYQ:ZTS · US98978V1035
PharmaceuticalsX-Large

360

56
EV / EBIT70
Price / Owner Earnings72
Owner Earnings Yield77
Dividend Yield97
Price/Sales69
EV / Gross Profit34
Price/Book15
Return on Capital91
Cash Return on Capital96
Return on Equity99
EBIT Margin94
Gross Profitability69
Cash Conversion22
Accruals34
Owner Earnings Margin94
Sales growth34
Profit Growth96
Long-Term EPS Growth37
Owner Earnings Growth39
Reinvestment46
Price momentum4
Debt load19
Refinancing96
Debt Payback31
Liquidity76
Analyst ratings14
Opinion Changes47
Price Target Upside90
Market mood85
Value Creation16/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Zoetis generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded2012
Employees8,817
Websitezoetis.com
ISINUS98978V1035
Last UpdateApr 2, 2026
Themes
Animal FeedLivestockPet CareHealth DiagnosticsPain ManagementGeneticsPet Food and SuppliesVaccinesAgricultureBiotechnologyHealth CareMedicalPharmaceutical

Description

Zoetis Inc. (Zoetis) operates in the animal health industry, focuses on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health.…

Analysis

Quality compounder

Zoetis Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 13.3×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 1% a year, against analyst forecasts of 7%. The price, in other words, assumes less than the experts do.

Growth is tepid; the safety picture is stretched. The company scores 16/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
93
2023202420252026

All-time high

93

Jun 2026

All-time low

28

Jan 2025

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
69
7
7
10
Price/Earnings
36
34
28
22
Price/Book
15
1
1
1
Dividend Yield
97
84
86
85
Value (overall)
92
45
17
23

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Zoetis with its peers
Merck (USA)
NYQ:MRK
35
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Pfizer Limited
NSI:PFIZER
65
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Corcept Therapeutics
NAQ:CORT
20
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Aquestive Therapeutics
NMQ:AQST
41
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →